Comparison of Preoperative Alpha-blockade for Resection of Paraganglioma and Pheochromocytoma.


Journal

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
ISSN: 1530-891X
Titre abrégé: Endocr Pract
Pays: United States
ID NLM: 9607439

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 11 04 2022
revised: 28 06 2022
accepted: 30 06 2022
pubmed: 10 7 2022
medline: 14 9 2022
entrez: 9 7 2022
Statut: ppublish

Résumé

Phenoxybenzamine (nonselective, noncompetitive alpha-blocker) is the preferred drug for preoperative treatment of pheochromocytoma, but doxazosin (selective, competitive alpha-blocker) may be equally effective. We compared the efficacy of doxazosin vs phenoxybenzamine. We conducted a prospective study of patients undergoing pheochromocytoma or paraganglioma resection by randomizing pretreatment with phenoxybenzamine or doxazosin at a single tertiary referral center. The high cost of phenoxybenzamine led to high crossover to doxazosin. Randomization was halted, and a consecutive historical cohort of phenoxybenzamine patients was included for a case-control study design. The efficacy of alpha-blockade was assessed with preinduction infusion of incremental doses of phenylephrine. The primary outcomes were mortality, cardiovascular complications, and intensive care unit admission. The secondary outcomes were hemodynamic instability index (proportion of operation outside of hemodynamic goals), adequacy of blockade by the phenylephrine titration test, and drug costs. Twenty-four patients were prospectively enrolled (doxazosin, n = 20; phenoxybenzamine, n = 4), and 15 historical patients treated with phenoxybenzamine were added (total phenoxybenzamine, n = 19). No major cardiovascular complications occurred in either group. The phenylephrine dose-response curves showed less blood pressure rise in the phenoxybenzamine than in the doxazosin group (linear regression coefficient = 0.008 vs 0.018, P = .01), suggesting better alpha-blockade in the phenoxybenzamine group. The median hemodynamic instability index was 14% vs 13% in the phenoxybenzamine and doxazosin groups, respectively (P = .56). The median highest daily cost of phenoxybenzamine was $442.20 compared to $5.06 for doxazosin. Phenoxybenzamine may blunt intraoperative hypertension better than doxazosin, but this difference did not translate to fewer cardiovascular complications and is offset by a considerably increased cost.

Identifiants

pubmed: 35809774
pii: S1530-891X(22)00548-1
doi: 10.1016/j.eprac.2022.06.013
pii:
doi:

Substances chimiques

Adrenergic alpha-Antagonists 0
Phenoxybenzamine 0TTZ664R7Z
Phenylephrine 1WS297W6MV
Doxazosin NW1291F1W8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

889-896

Informations de copyright

Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.

Auteurs

Catherine Y Zhu (CY)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California.

Joe C Hong (JC)

Department of Anesthesiology, UCLA David Geffen School of Medicine, Los Angeles, California.

Nirav V Kamdar (NV)

Department of Anesthesiology, UCLA David Geffen School of Medicine, Los Angeles, California.

Ming-Yeah Hu (MY)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California.

Chi-Hong Tseng (CH)

Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.

Jason S Lee (JS)

Department of Anesthesiology, UCLA David Geffen School of Medicine, Los Angeles, California.

Eric J Kuo (EJ)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California.

Run Yu (R)

Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, Los Angeles, California.

Jennifer Isorena (J)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California.

Michael W Yeh (MW)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California.

Masha J Livhits (MJ)

Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, California. Electronic address: mlivhits@mednet.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH